ArticlePloS one2014
C26 cancer-induced muscle wasting is IKKβ-dependent and NF-kappaB-independent.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 40 citations in OpenAlex.
- BCL6 regulates skeletal muscle mass and mitochondrial bioenergetics.Molecular metabolism · 2026Article
- C26 and CT26 colorectal cancer models exhibit divergent cachexia phenotypes, intramuscular inflammation, and protein turnover signaling.bioRxiv : the preprint server for biology · 2026Article
- NF-κB Signaling as a Central Driver of Cancer Cachexia.Cancers · 2026Review
- Signaling networks governing skeletal muscle growth, atrophy, and cachexiaSkeletal muscle · 2025Review
- Cancer-induced FOXP1 disrupts and reprograms skeletal-muscle circadian transcription in cachexia.Cell reports · 2025Article
- Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies.Journal of cachexia, sarcopenia and muscle · 2023Review
- MYTHO is a novel regulator of skeletal muscle autophagy and integrity.Nature communications · 2023Article
- Cancer cachexia: lessons from Drosophila.Disease models & mechanisms · 2022Review
- Article
- FoxP1 is a transcriptional repressor associated with cancer cachexia that induces skeletal muscle wasting and weakness.Journal of cachexia, sarcopenia and muscle · 2021Article
- Phenotypic features of cancer cachexia-related loss of skeletal muscle mass and function: lessons from human and animal studies.Journal of cachexia, sarcopenia and muscle · 2021Review
- Marked Increased Production of Acute Phase Reactants by Skeletal Muscle during Cancer Cachexia.Cancers · 2020Article
- Signaling Pathways That Control Muscle Mass.International journal of molecular sciences · 2020Review
- Derangements of amino acids in cachectic skeletal muscle are caused by mitochondrial dysfunction.Journal of cachexia, sarcopenia and muscle · 2020Article
- Muscle alterations in the development and progression of cancer-induced muscle atrophy: a review.Journal of applied physiology (Bethesda, Md. : 1985) · 2020Review
- Molecular Basis for the Therapeutic Effects of Exercise on Mitochondrial Defects.Frontiers in physiology · 2020Review
- Modeling Human Cancer-induced Cachexia.Cell reports · 2019Article
- Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.Journal of cachexia, sarcopenia and muscle · 2018Article
- Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival.Nature communications · 2017Article
- Molecular mechanism of sarcopenia and cachexia: recent research advances.Pflugers Archiv : European journal of physiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Existing data suggest that NF-kappaB signaling is a key regulator of cancer-induced skeletal muscle wasting. However, identification of the components of this signaling pathway and of the NF-κB transcription factors that regulate wasting is far from complete. In muscles of C26 tumor bearing mice, overexpression of dominant negative (d.n.) IKKβ blocked muscle wasting by 69% and the IκBα-super repressor blocked wasting by 41%. In contrast, overexpression of d.n. IKKα or d.n. NIK did not block C26-induced wasting. Surprisingly, overexpression of d.n. p65 or d.n. c-Rel did not significantly affect muscle wasting. Genome-wide mRNA expression arrays showed upregulation of many genes previously implicated in muscle atrophy. To test if these upregulated genes were direct targets of NF-κB transcription factors, we compared genome-wide p65 binding to DNA in control and cachectic muscle using ChIP-sequencing. Bioinformatic analysis of ChIP-sequencing data from control and C26 muscles showed very little p65 binding to genes in cachexia and little to suggest that upregulated p65 binding influences the gene expression associated with muscle based cachexia. The p65 ChIP-seq data are consistent with our finding of no significant change in protein binding to an NF-κB oligonucleotide in a gel shift assay, no activation of a NF-κB-dependent reporter, and no effect of d.n.p65 overexpression in muscles of tumor bearing mice. Taken together, these data support the idea that although inhibition of IκBα, and particularly IKKβ, blocks cancer-induced wasting, the alternative NF-κB signaling pathway is not required. In addition, the downstream NF-κB transcription factors, p65 and c-Rel do not appear to regulate the transcriptional changes induced by the C26 tumor. These data are consistent with the growing body of literature showing that there are NF-κB-independent substrates of IKKβ and IκBα that regulate physiological processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.